Canada exercised increased option for total of 40 million doses of mRNA vaccine candidate against COVID-19
On Dec. 7, 2020, Moderna announced that the Canadian Government had increased its confirmed order commitment by 20…
On Dec. 7, 2020, Moderna announced that the Canadian Government had increased its confirmed order commitment by 20…
On Dec. 7, 2020, Inovio Pharmaceuticals announced it had dosed its first subject in a Phase 2 clinical…
On Dec. 4, 2020, the U.S. Food and Drug Administration (FDA) authorized the first diagnostic test for at home collection…
On Dec. 4, 2020, it was reported in JAMA that high-dose influenza (commonly known as flu) vaccines are…
On Dec. 3, 2020, Moderna announced in a letter to the editor published in the New England Journal…
On Dec. 3, 2020, Inovio Pharmaceuticals announced the execution of an agreement with Kaneka Eurogentec an affiliate of…
On Nov. 30, 2020, Moderna announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273…
On Nov. 30, 2020, Novavax announced that two of the three planned late-stage efficacy trials for NVX-CoV2373 sponsored…
On Nov. 29, 2020, Moderna announced a supply agreement with the United Kingdom (UK) government for an additional…
On Nov. 25, 2020, Moderna announced that the European Commission (EC) has approved an agreement to secure 80…
On Nov. 25, 2020, BioNTech and InstaDeep announced a multi-year strategic collaboration aimed at applying the latest advances…
On Nov. 24, 2020, Roche announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental…
On Nov. 24, 2020, Northwestern University researchers announced they had developed a new artificial intelligence (A.I.) platform that…
On Nov. 24, 2020, published data from researchers at Mayo Clinic found that physical separation reduced the exposure…
On Nov. 23, 2020, the U.S. Food and Drug Administration (FDA) expanded the approved indication for Genentech’s Xofluza…
On Nov. 23, 2020, CytoDyn announced it had reached enrollment of 293 patients in its Phase 3 trial…
On Nov. 20, 2020, the ‘European Food Safety Authority reported that within the past month more than 300…
On Nov. 19, 2020, Cue Health announced that, as of November 9, the U.S. Department of Health and…
On Nov. 19, 2020, XBiotech announced data for its breakthrough candidate therapy for treating infections of influenza and…
On Nov. 19, 2020, Dallas-based company, Worlds Inc., the U.S. Air Force and Texas A&M University announced a…
On Nov. 17, 2020, Moderna announced a supply agreement with the government of the United Kingdom (UK) to…
On Nov. 17, 2020, Celdara Medical announced that the National Institute of Allergy and Infectious Disease (NIAID) of…
On Nov. 16, 2020, the UK Department for Health and Social Care Testing Innovation Fund announced £12.2M funding…
On Nov. 16, 2020, Moderna announced new data showing that mRNA-1273, its COVID-19 vaccine candidate, remained stable at…
On Nov. 16, 2020, Tonix Pharmaceuticals announced preliminary results following vaccination of non-human primates with TNX-1800 (modified horsepox…
On Nov. 16, 2020, INOVIO announced that it had received clearance from the the U.S. Food & Drug…
On Nov. 16, 2020, Aegis Sciences announced that it had launched a combined test for SARS-CoV-2 and influenza…
On Nov. 16, 2020, Moderna announced that the European Medicines Agency (EMA) human medicines committee (CHMP) had started…
On Nov. 15, 2020, an independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of…
On Nov. 13, 2020, Roche announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…